Table 3.
Comparison of Baseline Characteristics in 4 Categories
| Category | <1 | ≥1 to <2 | ≥2 to <4 | ≥4 to <10 | All |
|---|---|---|---|---|---|
| Mortality rate¶ | 0.53 | 1.54 | 2.83 | 7.13 | 1.83 |
| No. of trials | 6 | 10 | 3 | 3 | 22 |
| No. of patients | 15578 | 56480 | 12518 | 7266 | 91842 |
| Total patient-years | 61444 | 245570 | 47231 | 19395 | 373641 |
| Death (n) | 326 | 3791 | 1337 | 1383 | 6837 |
| Follow-up (y)* [no. of reporting trials] | 4.3 [6] | 5.4 [10] | 4.0 [3] | 2.7 [3] | 4.0 [22] |
| Female % [no. of reporting trials] | 47 [6] | 40 [10] | 32 [3] | 47 [3] | 40 [22] |
| (95% confidence interval) | (47–48) | (39–40) | (31–32) | (46–49) | |
| Age *[no. of reporting trials] | 59.0 [6] | 61.4 [10] | 63.1 [3] | 64.2 [3] | 61.6 [22] |
| (95% confidence interval) | (58.7–59.3) | (61.2–61.6) | (62.9–63.4) | (63.9–64.6) | |
| DM t* (y) [no. of reporting trials] | 7.2 [5] | 6.8 [9] | 9.2 [3] | 15.2 [3] | 8.9 [20] |
| (95% confidence interval) | (7.0–7.4) | (6.7–6.9) | (8.9–9.4) | (14.9–15.5) | |
| HbA1c * [no. of reporting trials] | 7.3 [6] | 7.6 [8] | 7.8 [3] | 7.5 [3] | 7.4 [20] |
| (95% confidence interval) | (7.3–7.4) | (7.6–7.7) | (7.8–7.9) | (7.5–7.6) | |
| BMI * [no. of reporting trials] | 30.0 [6] | 29.8 [9] | 30.3 [3] | 30.2 [3] | 29.9 [21] |
| (95% confidence interval) | (29.8–30.2) | (29.7–29.9) | (30.2–30.5) | (29.9–30.4) | |
| HTN %* [no. of reporting trials] | 73 [4] | 72 [7] | 69 [3] | 97 [2] | 73 [16] |
| (95% confidence interval) | (72–74) | (71–72) | (68–70) | (96–98) | |
| CVD % * [no. of reporting trials] | 3 [2] | 28 [8] | 70 [3] | 53 [3] | 31 [16] |
| (95% confidence interval) | (2–3) | (28–29) | (70–71) | (52–54) | |
| Smokers% *[no. of reporting trials] | 16 [6] | 15 [9] | 14 [3] | 9 [2] | 16 [20] |
| (95% confidence interval) | (16–17) | (15–16) | (13–15) | (8–9) | |
| SBP *(mmHg) no. of reporting trials] | 136 [6] | 140 [9] | 142 [3] | 145 [3] | 139 [21] |
| (95% confidence interval) | (135–136) | (139–140) | (140–142) | (144–146) | |
| SCr * (mg/dL) [no. of reporting trials] | 0.9 [5] | 0.9 [7] | 1.0 [2] | 1.8 [3] | 1.0 [17] |
| (95% confidence interval) | (0.9–0.9) | (0.9–0.9) | (0.9–1.0) | (1.8–1.9) | |
| Total C*(mg/dL) [no. of reporting trials] | 205 [5] | 195 [7] | 169 [1] | 192 [2] | 195 [15] |
| (95% confidence interval) | (203–206) | (193–196) | (168–171) | (191–194) | |
| LDL*(mg/dL) [no. of reporting trials] | 126 [4] | 117 [8] | 107 [2] | 99 [2] | 116 [16] |
| (95% confidence interval) | (126–127) | (116–118) | (106–108) | (98–101) | |
| Proteinuria %*[no. of reporting trials] | 9 [6] | 21 [7] | 52 [3] | 100 [3] | 32 [19] |
| (95% confidence interval) | (8–9) | (20–22) | (51–53) | (100–100) | |
| Retinopathy % *[no. of reporting trials] | 43 [3] | 18 [6] | 3 [2] | 55 [3] | 23 [14] |
| (95% confidence interval) | (42–45) | (18–19) | (2–3) | (54–56) | |
BMI indicates body mass index is the weight in kilograms divided by the square of the height in meters; CVD, sum of any cardiovascular disease incidence; DM t: diabetes mellitus duration, time; HbA1c, hemoglobin A1c, Total C: total cholesterol; LDL, low-density lipoprotein; SBP, systolic blood pressure; SCr, serum creatinine; Smoker, donates current smoker status.
Utilizing weight of patient sample; [] No. of contributed trials in each category;
Per 100 patient-years; percentage of subjects with micro/macroalbuminuria or proteinuria in trial as defined by publication.
To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. To convert the values for creatinine to milligrams per deciliter, divide by 88.4.
The body mass index is the weight in kilograms divided by the square of the height in meters.
Values were approximated to the hundredths place for death rate and to the tenth place for follow-up time, age, diabetes duration, BMI, HbA1c. SCr. CVD, hypertension, smoker, SBP, Total C, LDL, retinopathy, and microalbuminuria incidences were rounded off to the tens place.